Regencell Bioscience (NASDAQ:RGC) Shares Gap Up – Here’s Why

Posted by Francis Steltz on Oct 16th, 2026

Regencell Bioscience Holdings Limited (NASDAQ:RGC – Get Free Report) shares gapped up prior to trading on Friday. The stock had previously closed at $9.52, but opened at $10.31. Regencell Bioscience shares last traded at $9.8860, with a volume of 281,483 shares trading hands.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on RGC shares. Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Monday, September 21st. Wall Street Zen cut shares of Regencell Bioscience from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Regencell Bioscience currently has a consensus rating of “Sell”.

View Our Latest Stock Report on Regencell Bioscience

Regencell Bioscience Stock Performance

The business has a 50-day moving average of $6.17 and a two-hundred day moving average of $14.20.

Regencell Bioscience (NASDAQ:RGC – Get Free Report) last announced its earnings results on Wednesday, October 7th. The company reported ($0.01) earnings per share (EPS) for the quarter.

Institutional Trading of Regencell Bioscience

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Seven Fleet Capital Management LP acquired a new position in shares of Regencell Bioscience in the fourth quarter worth approximately $92,000. Amundi acquired a new stake in shares of Regencell Bioscience in the 1st quarter valued at about $219,000. Finally, Bank of America Corp DE increased its holdings in shares of Regencell Bioscience by 59,113.8% during the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after acquiring an additional 17,143 shares in the last quarter. Institutional investors own 0.13% of the company’s stock.

About Regencell Bioscience

(Get Free Report)

Regencell Bioscience Holdings Limited is a clinical-stage biotechnology company focused on developing traditional Chinese medicine (TCM) treatments for neurocognitive disorders and degenerative conditions. Its research has centered primarily on conditions such as dementia and attention-deficit/hyperactivity disorder (ADHD), with the goal of developing herbal formulations that may address underlying symptoms and disease-related challenges.

The company’s product development programs include proprietary TCM formulations intended for neurological and cognitive conditions.